Advertisement

NVRO

Nevro Corp.

Healthcare

Set alert

Price alert · NVRO

All alert types
5.84 0.00 0.00%
As of Apr 2, 2025
5.84 Day range 5.86

52-week range unavailable

YTD
+56.99%
1 year
-54.12%
Open
5.84
Prev close
5.84
Mkt cap
141.27M
Vol
751.50K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
5.84
High
5.86
Forward P/E
-1.46
Beta
0.93
Short ratio
3.78
Inst. own
103.83%
Dividend
0.00
Ex-div date
50-d avg
4.67
200-d avg
8.02
1y target
5.68

2Y chart

Chart tools
Interval
NVRO two-year price chart3.1712.321.430.539.7Apr 23Aug 23Jan 24Jun 24Nov 24Apr 25

Key statistics

Market cap
141.27M
Enterprise value
111.91M
Trailing P/E
0.00
Forward P/E
-1.46
PEG ratio
0.00
Price / sales
0.34
Price / book
0.52
EPS (TTM)
-1.87
Beta
0.93
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-16.54%
Revenue (TTM)
419.15M
Revenue growth
-6.70%
Free cash flow
-24.21M
Total cash
277.04M
Total debt
246.93M
Return on equity
-24.78%
Shares outstanding
37.47M
Short % of float
8.62%
50-day average
4.67
200-day average
8.02

Analyst view

Consensus: hold

Hold
Price target (mean) 5.68 -2.7% downside
Target (low)
4.00
Target (mean)
5.68
Target (high)
13.00
Ratings (0m) 16 0 buy · 11 hold · 5 sell
  • Strong buy0
  • Buy0
  • Hold11
  • Sell2
  • Strong sell3

Next earnings

Consensus EPS estimate -0.76857.

Earnings history

Financials — quick view

All financials
NVRO Revenue — quarterly 105.55M
2021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
NVRO Net income — quarterly -53.11M
2021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024
NVRO EPS — quarterly -1.43
2021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 2024

Earnings

NVRO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 11, 2024Sep 1, 2024-0.82-0.51+0.31+37.80%
Aug 6, 2024Jun 1, 2024-0.63-0.43+0.20+31.75%
May 7, 2024Mar 1, 2024-1.02-0.70+0.32+31.37%
Feb 21, 2024Dec 1, 2023-0.50-0.15+0.35+70.00%
Nov 1, 2023Sep 1, 2023-0.77-0.65+0.12+15.58%
Aug 1, 2023Jun 1, 2023-0.68-0.69-0.01-1.47%

Upgrades / downgrades

NVRO analyst upgrades and downgrades
DateFirmActionFromTo
Dec 18, 2024Truist SecuritiesmainHoldHold
Dec 11, 2024CitigroupmainNeutralNeutral
Dec 11, 2024Wells FargomainEqual-WeightEqual-Weight
Dec 9, 2024Canaccord GenuitymainHoldHold
Dec 2, 2024Morgan StanleydownEqual-WeightUnderweight
Nov 12, 2024Canaccord GenuitymainHoldHold

About Nevro Corp.

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
nevro.com

News

Your note

Sign in to keep a note on NVRO — it syncs with the Stock Master app.

Insider holders

NVRO insider holders
InsiderRelationLatest transactionDateShares held
DEMANE MICHAEL FDirectorStock Award(Grant)Sep 29, 2024496,562
FISCHER FRANK MDirectorStock Award(Grant)Mar 27, 202457,500
GROSSMAN DONALD KEITHDirectorStock Award(Grant)May 22, 2024230,613
KOSARAJU SRIDHARDirectorStock Award(Grant)Sep 29, 202442,342
MCCORMICK SHAWN TDirectorStock Award(Grant)May 22, 202446,035
O'BOYLE KEVIN CDirectorStock Award(Grant)May 22, 202443,396

Institution ownership

NVRO institution ownership
Holder% heldSharesValueReported
ArrowMark Colorado Holdings LLC11.72%4,391,25816.56MSep 29, 2024
Armistice Capital, LLC9.95%3,728,00014.05MSep 29, 2024
Blackrock Inc.8.19%3,067,20611.56MSep 29, 2024
Engaged Capital, LLC6.52%2,442,9569.21MSep 29, 2024
Vanguard Group Inc5.59%2,095,9387.90MSep 29, 2024
Braidwell LP 4.53%1,698,7686.40MSep 29, 2024

Fund ownership

NVRO fund ownership
Holder% heldSharesValueReported
Vanguard Explorer Fund, Inc.5.65%2,118,5277.99MJul 30, 2024
Vanguard Total Stock Market Index Fund3.08%1,152,8064.35MSep 29, 2024
iShares Russell 2000 ETF2.52%943,6803.56MOct 30, 2024
Meridian Growth Fund1.69%633,7482.39MSep 29, 2024
Vanguard Extended Market Index Fund1.53%574,0342.16MSep 29, 2024
Alger Weatherbie Specialized Growth Fund1.47%552,6102.08MJul 30, 2024
Advertisement